Corticosteroids in the adjunctive therapy of community-acquired pneumonia: An appraisal of recent meta-analyses of clinical tria

Journal of Thoracic Disease

Volumn 8, Issue 3, 2016, Pages E162-E171

  Feldman, Charles ^a   Anderson, Ronald ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Anti inflammatory; C reactive protein (CRP); Corticosteroids (CS); Inflammation; Macrolides; Metaanalysis; Methylprednisolone; Neutrophils

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CATECHOLAMINE; CLARITHROMYCIN; CORTICOSTEROID; DEXAMETHASONE; ERYTHROMYCIN; HYDROCORTISONE; MACROLIDE; METHYLPREDNISOLONE; PLACEBO; PREDNISONE;

ADJUVANT THERAPY; ANTIINFLAMMATORY ACTIVITY; COMMUNITY ACQUIRED PNEUMONIA; CONTINUOUS INFUSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; HUMAN; HYPERGLYCEMIA; INFLAMMATION; LENGTH OF STAY; META ANALYSIS (TOPIC); MORTALITY; MULTICENTER STUDY (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY DISTRESS SYNDROME; REVIEW; RISK BENEFIT ANALYSIS; SEPTIC SHOCK; SUPERINFECTION; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION; UPPER GASTROINTESTINAL BLEEDING;

EID: 84962145309     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.21037/jtd.2016.02.43     Document Type: Review

References (44)

1. Steel HC, Cockeran R, Anderson R, et al. Overview of community-acquired pneumonia and the role of inflammatory mechanisms in the immunopathogenesis of severe pneumococcal disease. Mediators Inflamm 2013;2013:490346.
2. Wunderink RG. CAP death: what goes wrong when everything is right? Lancet Infect Dis 2015;15:995-6.
3. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;385:117-71.
4. Walden AP, Clarke GM, McKechnie S, et al. Patients with community acquired pneumonia admitted to European intensive care units: an epidemiological survey of the GenOSept cohort. Crit Care 2014;18:R58.
5. Millett ER, De Stavola BL, Quint JK, et al. Risk factors for hospital admission in the 28 days following a communityacquired pneumonia diagnosis in older adults, and their contribution to increasing hospitalisation rates over time: a cohort study. BMJ Open 2015;5:e008737.
6. Karlström A, Boyd KL, English BK, et al. Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza. J Infect Dis 2009;199:311-9.
7. Liapikou A, Torres A. Current treatment of communityacquired pneumonia. Expert Opin Pharmacother 2013;14:1319-32.
8. Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med 2014;371:1619-28.
9. Prina E, Ranzani OT, Torres A. Community-acquired pneumonia. Lancet 2015;386:1097-108.
10. Shindo Y, Ito R, Kobayashi D, et al. Risk factors for 30-day mortality in patients with pneumonia who receive appropriate initial antibiotics: an observational cohort study. Lancet Infect Dis 2015;15:1055-65.
11. Meijvis SC, van de Garde EM, Rijkers GT, et al. Treatment with anti-inflammatory drugs in communityacquired pneumonia. J Intern Med 2012;272:25-35.
12. Sibila O, Ferrer M, Agustí C, et al. Corticosteroids as adjunctive treatment in community-acquired pneumonia. Minerva Anestesiol 2014;80:1336-44.
13. Feldman C, Anderson R. Community-acquired pneumonia: pathogenesis of acute cardiac events and potential adjunctive therapies. Chest 2015;148:523-32.
14. Siemieniuk RA, Meade MO, Alonso-Coello P, et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. Ann Intern Med 2015;163:519-28.
15. Barnes PJ. Glucocorticosteroids: current and future directions. Br J Pharmacol 2011;163:29-43.
16. Cruz-Topete D, Cidlowski JA. One hormone, two actions: anti-and pro-inflammatory effects of glucocorticoids. Neuroimmunomodulation 2015;22:20-32.
17. Tintinger GR, Anderson R, Feldman C. Pharmacological approaches to regulate neutrophil activity. Semin Immunopathol 2013;35:395-409.
18. Westphal JF. Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 2000;50:285-95.
19. Common medications classified as weak, moderate and strong inhibitors of CYP3A4. Available online: http://www.ebmconsult.com/articles/medications-inhibitorscyp3a4-enzyme
20. Matoulková P, Pávek P, Malỳ J, et al. Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction. Expert Opin Drug Metab Toxicol 2014;10:425-35.
21. Fost DA, Leung DY, Martin RJ, et al. Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy. J Allergy Clin Immunol 1999;103:1031-5.
22. Saffar AS, Dragon S, Ezzati P, et al. Phosphatidylinositol 3-kinase and p38 mitogen-activated protein kinase regulate induction of Mcl-1 and survival in glucocorticoid-treated human neutrophils. J Allergy Clin Immunol 2008;121:492-498.e10.
23. Bergquist M, Jirholt P, Nurkkala M, et al. Glucocorticoid receptor function is decreased in neutrophils during endotoxic shock. J Infect 2014;69:113-22.
24. Dilisio MF. Osteonecrosis following short-term, low-dose oral corticosteroids: a population-based study of 24 million patients. Orthopedics 2014;37:e631-6.
25. Richards RN. Side effects of short-term oral corticosteroids. J Cutan Med Surg 2008;12:77-81.
26. Torres A, Ferrer M. What's new in severe communityacquired pneumonia? Corticosteroids as adjunctive treatment to antibiotics. Intensive Care Med 2015. [Epub ahead of print].
27. Chen Y, Li K, Pu H, et al. Corticosteroids for pneumonia. Cochrane Database Syst Rev 2011;(3):CD007720.
28. Marti C, Grosgurin O, Harbarth S, et al. Adjunctive corticotherapy for community acquired pneumonia: a systematic review and meta-analysis. PLoS One 2015;10:e0144032.
29. Horita N, Otsuka T, Haranaga S, et al. Adjunctive Systemic Corticosteroids for Hospitalized Community-Acquired Pneumonia: Systematic Review and Meta-Analysis 2015 Update. Sci Rep 2015;5:14061.
30. Chen LP, Chen JH, Chen Y, et al. Efficacy and safety of glucocorticoids in the treatment of community-acquired pneumonia: A meta-analysis of randomized controlled trials. World J Emerg Med 2015;6:172-8.
31. Wan YD, Sun TW, Liu ZQ, et al. Efficacy and safety of corticosteroids for community-acquired pneumonia: a systematic review and meta-analysis. Chest 2016;149:209-19.
32. Cheng M, Pan ZY, Yang J, et al. Corticosteroid therapy for severe community-acquired pneumonia: a meta-analysis. Respir Care 2014;59:557-63.
33. Blum CA, Nigro N, Briel M, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebocontrolled trial. Lancet 2015;385:1511-8.
34. Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 2015;313:677-86.
35. Tagami T, Matsui H, Horiguchi H, et al. Low-dose corticosteroid use and mortality in severe communityacquired pneumonia patients. Eur Respir J 2015;45:463-72.
36. Extended Steroid in CAP(e) (ESCAPe). Available online: https://clinicaltrials.gov/ct2/show/NCT01283009
37. Santeon-CAP; Dexamethasone in Community-acquired Pneumonia. Available online: https://clinicaltrials.gov/ct2/show/NCT01743755
38. ADjunctive coRticosteroid trEatment iN criticAlly ilL Patients With Septic Shock (ADRENAL). Available online: https://clinicaltrials.gov/ct2/show/NCT01448109
39. Restrepo MI, Anzueto A, Torres A. Corticosteroids for Severe Community-Acquired Pneumonia: Time to Change Clinical Practice. Ann Intern Med 2015;163:560-1.
40. Wunderink RG. Corticosteroids for severe communityacquired pneumonia: not for everyone. JAMA 2015;313:673-4.
41. Ricard JD, Messika J. Low-dose corticosteroids during severe community-acquired pneumonia: end of the story. Eur Respir J 2015;45:305-7.
42. Annane D. Corticosteroids and pneumonia: time to change practice. Lancet 2015;385:1484-5.
43. Baskar V, Sum CF, Lim SC. Prednisone for communityacquired pneumonia: not yet time. Lancet 2015;386:431.
44. Siemieniuk RA, Guyatt GH. Corticosteroids in the treatment of community-acquired pneumonia: an evidence summary. Pol Arch Med Wewn 2015;125:570-5.